In association with PDCI Market Access & Novartis UK
Why should you attend this event?
Upon completion of this MasterClass, attendees will have an understanding of:
- Global pricing and reimbursement elements and principles
- Pricing theory and research methods
- Latest information on the expected changes in the UK (NICE, PPRI, SMC)
- P&R/HTA in major EU markets and Canada
- Launch sequencing, price corridors
Where does the event take place?
This MasterClass will take place in Central London, UK
|
What is this MasterClass about?
No single factor influences profits more than price. Accordingly, it is imperative to develop an effective pricing strategy early in the product life cycle. However, an optimal price for reimbursement / market access in one market may not be optimal in others and the pervasiveness of international price referencing and parallel trade creates pressures for price convergence often at sub-optimal levels in key markets. Moreover, health technology assessment (HTA) agencies have taken on increasingly important roles in assessing clinical and cost effectiveness and their assessments have spawned a new environment of risk sharing agreements and patient access schemes. By starting early (i.e., well before market authorisation) it is possible to build effective strategies that establish optimal prices by market, provide evidence to maximise reimbursement, and mitigate the effects of price referencing and parallel trade.
Who is leading this MasterClass?
Neil Palmer, President & Principal Consultant, PDCI Market Access
Neil Palmer is President and Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing and reimbursement consultancy founded as Palmer D'Angelo Consulting Inc (PDCI) in 1996. In addition to PDCI, Neil has worked with RTI Health Solutions, the Patented Medicine Prices Review Board (PMPRB), the Health Division of Statistics Canada and the research group of the Kellogg Centre for Advanced Studies in Primary Care in Montreal. He has more than 20 years of experience in pharmaceutical pricing and reimbursement and is a frequent speaker at pharmaceutical conferences in North America and Europe. http://www.pdci.ca
Martin Brown, Head of Health Economics and Outcomes Research, Novartis Pharmaceuticals UK Limited
Martin Brown has over twelve years' experience working in the health economic and outcomes research field in the pharmaceutical and biopharmaceutical industry. The majority of his experience has been in global health economic/outcomes departments at Pfizer and UCB, where he was the Global Head of Health Economics. These roles involved providing advice and recommendations to clinical development teams in order to ensure that the necessary clinical and cost-effectiveness evidence was generated for healthcare guidance and reimbursement bodies. http://www.novartis.co.uk
Tony Hod
Masterclass agenda
Workshop hosts' experience and qualifications
Purpose and scope of the workshop
Introduction to Global Pricing, Reimbursement & Market Access
Price regulation (free pricing, negotiated pricing, regulated pricing)
Internal & external price referencing
Role of HTA, Health Economics
Role of Regions in implementing administering national policies
Risk Sharing, Listing Agreements
Role of Pricing Theory and Research
Research flow: qualitative and quantitative methods
Description of pricing research approaches (discrete choice, conjoint, value mapping, etc)
Comparison of relative strengths and weaknesses,
Challenges of conducting pharmaceutical pricing research
Overview on National Market Access/HTA in the UK
NICE, SMC
Recent developments such as Patient Access Schemes and Flexible Pricing
How the new government is likely to/has changed things
Value based pricing
Overview of Market Access/HTA in EU major markets & Canada
Germany, France, Spain, Italy, Canada
Country updates: recent developments in pricing
Role of Health Economics / HTA in each market
An Overview of Global Pharmaceutical Launch Pricing Issues
Organising for global pricing
Launch sequence
Price corridors versus uniform global price
Managing price corridors
Parallel trade
Implications of exchange rate movements
VENUE
Holiday Inn Bloomsbury
Coram Street, London, United Kingdom
Holiday Inn London-Bloomsbury is just 2 minutes' walk from the Tube at Russell Square station, for speedy connections across the capital. We're 10 minutes by bus from Eurostar connections at St Pancras station, and a 45-minute taxi ride from London Heathrow Airport. Check into your stylish Guest room, air-conditioned and connected to wireless Internet.
A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM
copyright ©
2024
SAE Media Group
|